Biobetters pp 183-202 | Cite as

Perspectives on Engineering Biobetter Therapeutic Proteins with Greater Stability in Inflammatory Environments

Part of the AAPS Advances in the Pharmaceutical Sciences Series book series (AAPS, volume 19)

Abstract

Rapid progression of genetic engineering technology has accelerated the development and availability of protein-based biopharmaceuticals for clinical use. However, their unique and complex structures render them susceptible to a plethora of post-translational modifications (PTMs) as well as chemical degradative processes they may encounter in distinct in vivo environments. Among the more common degradative reactions that can impact the structure and function of therapeutic proteins are oxidation, proteolysis, phosphorylation, and deamidation. Several PTMs such as oxidation further render modified proteins vulnerable to aggregation or proteolytic degradation by enzymatic or non-enzymatic mechanisms (Torosantucci et al., Pharm Res 31(3):541–553, 2014). Degradation of a therapeutic protein in vivo becomes problematic when the structural modification alters its intended function and safety or efficacy profile (Foye, Lippincott Williams & Wilkins, Philadelphia, 2008). As a result of protein aggregation or degradation, therapeutic activity can be decreased, increased, or altered to have off-target effects. Protein degradation or aggregation could be facilitated under inflammatory circumstances in diverse clinical settings such as cancer, chronic inflammatory diseases, organ transplants, infectious diseases, and cardiovascular disorders, and can exacerbate an inflammatory response with unintended consequences (Chennamsetty et al., Proc Natl Acad Sci U S A 106(29):11937–11942, 2009; Hermeling et al., Pharm Res, 21(6):897–903, 2004). Therefore, characterizing and controlling the degradation or aggregation profiles for a therapeutic protein, especially for indications where the physiological environment presents additional opportunity for instability, is an essential component of a drug manufacturer’s control strategy. Evaluating a manufacturer’s control strategy is a key risk assessment tool for the regulation of investigational and licensed biologic drugs for human use. Better risk assessment can result from (1) greater characterization of critical structural modifications that can influence therapeutic protein function (2), application of sensitive and suitable methods to objectively measure protein modifications, and (3) use of relevant preclinical models or human tissue samples for predicting the in vivo impact of the inflammatory environment on such protein alterations. The increasing number of novel investigational drugs and the simultaneous demand for safer and more effective drugs warrants the need to examine the mechanisms by which therapeutic proteins are modified in vitro and in vivo, as well as apply modern analytical and genetic engineering techniques to design biobetter biologic drugs with improved safety and efficacy profiles. This chapter will examine factors known to alter the stability of therapeutic proteins in vivo, potential interactions of susceptible proteins with the inflammatory environment, and review some challenges and potential strategies for designing biobetters.

Keywords

Hydrocarbon Superoxide Cysteine Aldehyde Adduct 

Notes

Disclosure

The views expressed in this article are those of the author and do not necessarily reflect the official policy or position of the U.S. Food and Drug Administration and the Department of Health and Human Services, nor does mention of trade names, commercial products, or organizations imply endorsement by the U.S. Government.

References

  1. Adibzadeh M et al (1992) Activity of liposomal interleukin-2 in vitro. Mol Biother 4(1):24–28PubMedGoogle Scholar
  2. Almeida MR, Saraiva MJ (2012) Clearance of extracellular misfolded proteins in systemic amyloidosis: experience with transthyretin. FEBS Lett 586(18):2891–2896PubMedGoogle Scholar
  3. Amin KA, Mohamed BM, El-Wakil MA, Ibrahem SO (2012) Impact of breast cancer and combination chemotherapy on oxidative stress, hepatic and cardiac markers. J Breast Cancer 15(3):306–312PubMedCentralPubMedGoogle Scholar
  4. Amor S et al (2014) Inflammation in neurodegenerative diseases–an update. Immunology 142(2):151–166PubMedCentralPubMedGoogle Scholar
  5. Ano Bom AP et al (2012) Mutant p53 aggregates into prion-like amyloid oligomers and fibrils: implications for cancer. J Biol Chem 287(33):28152–28162PubMedCentralPubMedGoogle Scholar
  6. Arakawa T, Prestrelski SJ, Narhi LO, Boone TC, Kenney WC (1993) Cysteine 17 of recombinant human granulocyte-colony stimulating factor is partially solvent-exposed. J Protein Chem 12(5):525–531PubMedGoogle Scholar
  7. Areti A, Yerra VG, Naidu V, Kumar A (2014) Oxidative stress and nerve damage: role in chemotherapy induced peripheral neuropathy. Redox Biol 2:289–295PubMedCentralPubMedGoogle Scholar
  8. Aryal B, Jeong J, Rao VA (2014) Doxorubicin-induced carbonylation and degradation of cardiac myosin binding protein C promote cardiotoxicity. Proc Natl Acad Sci U S A 111(5):2011–2016PubMedCentralPubMedGoogle Scholar
  9. Bailon P et al (2001) Rational design of a potent, long-lasting form of interferon: a 40 kDa branched polyethylene glycol-conjugated interferon alpha-2a for the treatment of hepatitis C. Bioconjug Chem 12(2):195–202PubMedGoogle Scholar
  10. Beals JM, Shanafelt AB (2006) Enhancing exposure of protein therapeutics. Drug Discov Today Technol 3(1):87–94PubMedGoogle Scholar
  11. Bennett CL et al (2004) Pure red-cell aplasia and epoetin therapy. N Engl J Med 351(14):1403–1408PubMedGoogle Scholar
  12. Bird GH et al (2010) Hydrocarbon double-stapling remedies the proteolytic instability of a lengthy peptide therapeutic. Proc Natl Acad Sci U S A 107(32):14093–14098PubMedCentralPubMedGoogle Scholar
  13. Bossi O et al (2008) UV irradiation increases ROS production via PKCdelta signaling in primary murine fibroblasts. J Cell Biochem 105(1):194–207PubMedGoogle Scholar
  14. Boyd SE, Pike RN, Rudy GB, Whisstock JC, Garcia de la Banda M (2005) PoPS: a computational tool for modeling and predicting protease specificity. J Bioinform Comput Biol 3(3):551–585PubMedGoogle Scholar
  15. Braun CR et al (2010) Photoreactive stapled BH3 peptides to dissect the BCL-2 family interactome. Chem Biol 17(12):1325–1333PubMedCentralPubMedGoogle Scholar
  16. Brems DN, Brown PL, Becker GW (1990) Equilibrium denaturation of human growth hormone and its cysteine-modified forms. J Biol Chem 265(10):5504–5511PubMedGoogle Scholar
  17. Butterfield DA, Kanski J (2001) Brain protein oxidation in age-related neurodegenerative disorders that are associated with aggregated proteins. Mech Ageing Dev 122(9):945–962PubMedGoogle Scholar
  18. Calabrese V et al (2006) Redox regulation of cellular stress response in neurodegenerative disorders. Ital J Biochem 55(3–4):263–282PubMedGoogle Scholar
  19. Chennamsetty N, Voynov V, Kayser V, Helk B, Trout BL (2009) Design of therapeutic proteins with enhanced stability. Proc Natl Acad Sci U S A 106(29):11937–11942PubMedCentralPubMedGoogle Scholar
  20. Cines DB, Yasothan U, Kirkpatrick P (2008) Romiplostim. Nat Rev Drug Discov 7(11):887–888PubMedGoogle Scholar
  21. Clark R et al (1996) Long-acting growth hormones produced by conjugation with polyethylene glycol. J Biol Chem 271(36):21969–21977PubMedGoogle Scholar
  22. Comhair SA, Bhathena PR, Dweik RA, Kavuru M, Erzurum SC (2000) Rapid loss of superoxide dismutase activity during antigen-induced asthmatic response. Lancet 355(9204):624PubMedGoogle Scholar
  23. Dabbs RA, Wyatt AR, Yerbury JJ, Ecroyd H, Wilson MR (2013) Extracellular chaperones. Top Curr Chem 328:241–268PubMedGoogle Scholar
  24. De Rosa R et al (2005) Intranasal administration of nerve growth factor (NGF) rescues recognition memory deficits in AD11 anti-NGF transgenic mice. Proc Natl Acad Sci U S A 102(10):3811–3816PubMedCentralPubMedGoogle Scholar
  25. Della Pina P et al (2012) Biological drugs: classic adverse effects and new clinical evidences. Cardiovasc Toxicol 12(4):285–297PubMedGoogle Scholar
  26. Dobson CM (2006) Protein aggregation and its consequences for human disease. Protein Pept Lett 13(3):219–227PubMedGoogle Scholar
  27. Doroshow JH, Locker GY, Myers CE (1980) Enzymatic defenses of the mouse heart against reactive oxygen metabolites: alterations produced by doxorubicin. J Clin Invest 65(1):128–135PubMedCentralPubMedGoogle Scholar
  28. Dulaney SB, Huang X (2012) Strategies in synthesis of heparin/heparan sulfate oligosaccharides: 2000-present. Adv Carbohydr Chem Biochem 67:95–136PubMedCentralPubMedGoogle Scholar
  29. Egrie JC, Browne JK (2001) Development and characterization of novel erythropoiesis stimulating protein (NESP). Br J Cancer 84(S1):3–10PubMedCentralPubMedGoogle Scholar
  30. Egrie JC, Dwyer E, Browne JK, Hitz A, Lykos MA (2003) Darbepoetin alfa has a longer circulating half-life and greater in vivo potency than recombinant human erythropoietin. Exp Hematol 31(4):290–299PubMedGoogle Scholar
  31. Elliott S et al (2004) Control of rHuEPO biological activity: the role of carbohydrate. Exp Hematol 32(12):1146–1155PubMedGoogle Scholar
  32. Foye WOLTLWDA (2008) Foye’s principles of medicinal chemistry. Lippincott Williams & Wilkins, PhiladelphiaGoogle Scholar
  33. Garay RP, El-Gewely R, Armstrong JK, Garratty G, Richette P (2012) Antibodies against polyethylene glycol in healthy subjects and in patients treated with PEG-conjugated agents. Expert Opin Drug Deliv 9(11):1319–1323PubMedGoogle Scholar
  34. Gaspar MM, Perez-Soler R, Cruz ME (1996) Biological characterization of L-asparaginase liposomal formulations. Cancer Chemother Pharmacol 38(4):373–377PubMedGoogle Scholar
  35. Gasteiger E et al (2005) Protein Identification and analysis tools on the ExPASy server. In: Walker J (ed) The proteomics protocols handbook. Humana, Totowa, pp 571–607Google Scholar
  36. Giasson BI et al (2000) Oxidative damage linked to neurodegeneration by selective alpha-synuclein nitration in synucleinopathy lesions. Science 290(5493):985–989PubMedGoogle Scholar
  37. Gillies SD et al (2002) Bi-functional cytokine fusion proteins for gene therapy and antibody-targeted treatment of cancer. Cancer Immunol Immunother 51(8):449–460PubMedGoogle Scholar
  38. Goldenberg MM (1999) Etanercept, a novel drug for the treatment of patients with severe, active rheumatoid arthritis. Clin Ther 21(1):75–87, discussion 71–72PubMedGoogle Scholar
  39. Goth L (2008) Catalase deficiency and type 2 diabetes. Diabetes Care 31(12):e93PubMedGoogle Scholar
  40. Gsponer J, Babu MM (2012) Cellular strategies for regulating functional and nonfunctional protein aggregation. Cell Rep 2(5):1425–1437PubMedCentralPubMedGoogle Scholar
  41. Han J et al (2008) Involvement of protective autophagy in TRAIL resistance of apoptosis-defective tumor cells. J Biol Chem 283(28):19665–19677PubMedCentralPubMedGoogle Scholar
  42. Hazell LJ, van den Berg JJ, Stocker R (1994) Oxidation of low-density lipoprotein by hypochlorite causes aggregation that is mediated by modification of lysine residues rather than lipid oxidation. Biochem J 302(Pt 1):297–304PubMedCentralPubMedGoogle Scholar
  43. Heikoop JC, van den Boogaart P, Mulders JW, Grootenhuis PD (1997) Structure-based design and protein engineering of intersubunit disulfide bonds in gonadotropins. Nat Biotechnol 15(7):658–662PubMedGoogle Scholar
  44. Herczenik E et al (2007) Activation of human platelets by misfolded proteins. Arterioscler Thromb Vasc Biol 27(7):1657–1665PubMedGoogle Scholar
  45. Hermeling S, Crommelin DJ, Schellekens H, Jiskoot W (2004) Structure-immunogenicity relationships of therapeutic proteins. Pharm Res 21(6):897–903PubMedGoogle Scholar
  46. Hochgrebe T, Pankhurst GJ, Wilce J, Easterbrook-Smith SB (2000) pH-dependent changes in the in vitro ligand-binding properties and structure of human clusterin. Biochemistry 39(6):1411–1419PubMedGoogle Scholar
  47. Iborra M et al (2011) Role of oxidative stress and antioxidant enzymes in Crohn’s disease. Biochem Soc Trans 39(4):1102–1106PubMedGoogle Scholar
  48. Inoguchi T et al (2003) Protein kinase C-dependent increase in reactive oxygen species (ROS) production in vascular tissues of diabetes: role of vascular NAD(P)H oxidase. J Am Soc Nephrol 14(8 Suppl 3):S227–S232PubMedGoogle Scholar
  49. Ishikawa M et al (1992) The substitution of cysteine 17 of recombinant human G-CSF with alanine greatly enhanced its stability. Cell Struct Funct 17(1):61–65PubMedGoogle Scholar
  50. Jasin HE (1983) Generation of IgG aggregates by the myeloperoxidase-hydrogen peroxide system. J Immunol 130(4):1918–1923PubMedGoogle Scholar
  51. Jazayeri JA, Carroll GJ (2008) Fc-based cytokines : prospects for engineering superior therapeutics. BioDrugs 22(1):11–26PubMedGoogle Scholar
  52. Jiang Y, Jiang W, Qiu Y, Dai W (2011) Effect of a structurally modified human granulocyte colony stimulating factor, G-CSFa, on leukopenia in mice and monkeys. J Hematol Oncol 4:28PubMedCentralPubMedGoogle Scholar
  53. Jomova K, Vondrakova D, Lawson M, Valko M (2010) Metals, oxidative stress and neurodegenerative disorders. Mol Cell Biochem 345(1–2):91–104PubMedGoogle Scholar
  54. Kahook MY et al (2010) High-molecular-weight aggregates in repackaged bevacizumab. Retina 30(6):887–892PubMedGoogle Scholar
  55. Kaufman RJ (1998) Post-translational modifications required for coagulation factor secretion and function. Thromb Haemost 79(6):1068–1079PubMedGoogle Scholar
  56. Keeney PM et al (2009) Mitochondrial gene therapy augments mitochondrial physiology in a Parkinson’s disease cell model. Hum Gene Ther 20(8):897–907PubMedCentralPubMedGoogle Scholar
  57. Kim TH et al (2012) PEG-transferrin conjugated TRAIL (TNF-related apoptosis-inducing ligand) for therapeutic tumor targeting. J Control Release 162(2):422–428PubMedCentralPubMedGoogle Scholar
  58. Kirkham P, Rahman I (2006) Oxidative stress in asthma and COPD: antioxidants as a therapeutic strategy. Pharmacol Ther 111(2):476–494PubMedGoogle Scholar
  59. Kroon DJ, Baldwin-Ferro A, Lalan P (1992) Identification of sites of degradation in a therapeutic monoclonal antibody by peptide mapping. Pharm Res 9(11):1386–1393PubMedGoogle Scholar
  60. Labbadia J et al (2012) Suppression of protein aggregation by chaperone modification of high molecular weight complexes. Brain 135(Pt 4):1180–1196PubMedCentralPubMedGoogle Scholar
  61. Lam XM, Yang JY, Cleland JL (1997) Antioxidants for prevention of methionine oxidation in recombinant monoclonal antibody HER2. J Pharm Sci 86(11):1250–1255PubMedGoogle Scholar
  62. Lawson KV, Rose TE, Harran PG (2013) Template-constrained macrocyclic peptides prepared from native, unprotected precursors. Proc Natl Acad Sci U S A 110(40):E3753–E3760PubMedCentralPubMedGoogle Scholar
  63. Leach JK, Van Tuyle G, Lin PS, Schmidt-Ullrich R, Mikkelsen RB (2001) Ionizing radiation-induced, mitochondria-dependent generation of reactive oxygen/nitrogen. Cancer Res 61(10):3894–3901PubMedGoogle Scholar
  64. Li J et al (2001) Thrombocytopenia caused by the development of antibodies to thrombopoietin. Blood 98(12):3241–3248PubMedGoogle Scholar
  65. Lochhead JJ, Thorne RG (2012) Intranasal delivery of biologics to the central nervous system. Adv Drug Deliv Rev 64(7):614–628PubMedGoogle Scholar
  66. Lopert P, Day BJ, Patel M (2012) Thioredoxin reductase deficiency potentiates oxidative stress, mitochondrial dysfunction and cell death in dopaminergic cells. PLoS One 7(11):e50683PubMedCentralPubMedGoogle Scholar
  67. Lu HS et al (1992) Folding and oxidation of recombinant human granulocyte colony stimulating factor produced in Escherichia coli. Characterization of the disulfide-reduced intermediates and cysteine––serine analogs. J Biol Chem 267(13):8770–8777PubMedGoogle Scholar
  68. Lu HS et al (1999) Chemical modification and site-directed mutagenesis of methionine residues in recombinant human granulocyte colony-stimulating factor: effect on stability and biological activity. Arch Biochem Biophys 362(1):1–11PubMedGoogle Scholar
  69. Luxon BA, Grace M, Brassard D, Bordens R (2002) Pegylated interferons for the treatment of chronic hepatitis C infection. Clin Ther 24(9):1363–1383PubMedGoogle Scholar
  70. Mansour RB et al (2008) Increased levels of autoantibodies against catalase and superoxide dismutase associated with oxidative stress in patients with rheumatoid arthritis and systemic lupus erythematosus. Scand J Rheumatol 37(2):103–108PubMedGoogle Scholar
  71. Matheson NR, Wong PS, Travis J (1979) Enzymatic inactivation of human alpha-1-proteinase inhibitor by neutrophil myeloperoxidase. Biochem Biophys Res Commun 88(2):402–409PubMedGoogle Scholar
  72. Matheson NR, Janoff A, Travis J (1982) Enzymatic oxidation of alpha-1-proteinase inhibitor in abnormal tissue turnover. Mol Cell Biochem 45(2):65–71PubMedGoogle Scholar
  73. McGoff P, Scher DS (2000) Solution formulation of proteins/peptides. In: McNally EJ (ed) Protein formulation and delivery. Marcel Dekker, New York, pp 133–152Google Scholar
  74. Meredith SC (2005) Protein denaturation and aggregation: cellular responses to denatured and aggregated proteins. Ann N Y Acad Sci 1066:181–221PubMedGoogle Scholar
  75. Migliore MM, Vyas TK, Campbell RB, Amiji MM, Waszczak BL (2010) Brain delivery of proteins by the intranasal route of administration: a comparison of cationic liposomes versus aqueous solution formulations. J Pharm Sci 99(4):1745–1761PubMedGoogle Scholar
  76. Mohsenzadegan M, Mirshafiey A (2012) The immunopathogenic role of reactive oxygen species in Alzheimer disease. Iran J Allergy Asthma Immunol 11(3):203–216PubMedGoogle Scholar
  77. Mulinacci F, Poirier E, Capelle MA, Gurny R, Arvinte T (2013) Influence of methionine oxidation on the aggregation of recombinant human growth hormone. Eur J Pharm Biopharm 85(1):42–52PubMedGoogle Scholar
  78. Nilsson P et al (2013) A2 secretion and plaque formation depend on autophagy. Cell Rep 5(1):61–69PubMedGoogle Scholar
  79. Park JB et al (2010) PEGylation of bacterial cocaine esterase for protection against protease digestion and immunogenicity. J Control Release 142(2):174–179PubMedCentralPubMedGoogle Scholar
  80. Patel J, Kothari R, Tunga R, Ritter NM, Tunga BS (2011) Stability considerations for biopharmaceuticals. Part 1: overview of protein and peptide degradation pathways. Bioprocess Int 9:20–31Google Scholar
  81. Pavisic R et al (2010) Recombinant human granulocyte colony stimulating factor pre-screening and screening of stabilizing carbohydrates and polyols. Int J Pharm 387(1–2):110–119PubMedGoogle Scholar
  82. Perl A (2013) Oxidative stress in the pathology and treatment of systemic lupus erythematosus. Nat Rev Rheumatol 9(11):674–686PubMedCentralPubMedGoogle Scholar
  83. Phillips NB et al (2010) Supramolecular protein engineering: design of zinc-stapled insulin hexamers as a long acting depot. J Biol Chem 285(16):11755–11759PubMedCentralPubMedGoogle Scholar
  84. Poon S, Easterbrook-Smith SB, Rybchyn MS, Carver JA, Wilson MR (2000) Clusterin is an ATP-independent chaperone with very broad substrate specificity that stabilizes stressed proteins in a folding-competent state. Biochemistry 39(51):15953–15960PubMedGoogle Scholar
  85. Rajadhyaksha M, Boyden T, Liras J, El-Kattan A, Brodfuehrer J (2011) Current advances in delivery of biotherapeutics across the blood–brain barrier. Curr Drug Discov Technol 8(2):87–101PubMedGoogle Scholar
  86. Raju TS, Scallon BJ (2006) Glycosylation in the Fc domain of IgG increases resistance to proteolytic cleavage by papain. Biochem Biophys Res Commun 341(3):797–803PubMedGoogle Scholar
  87. Rangel LP, Costa DC, Vieira TC, Silva JL (2014) The aggregation of mutant p53 produces prion-like properties in cancer. Prion 8(1):75–84PubMedGoogle Scholar
  88. Raso SW et al (2005) Aggregation of granulocyte-colony stimulating factor in vitro involves a conformationally altered monomeric state. Protein Sci 14(9):2246–2257PubMedCentralPubMedGoogle Scholar
  89. Ratanji KD, Derrick JP, Dearman RJ, Kimber I (2014) Immunogenicity of therapeutic proteins: influence of aggregation. J Immunotoxicol 11(2):99–109PubMedCentralPubMedGoogle Scholar
  90. Reily C et al (2013) Mitochondrially targeted compounds and their impact on cellular bioenergetics. Redox Biol 1(1):86–93PubMedCentralPubMedGoogle Scholar
  91. Reubsaet JL et al (1998) Oxidation of recombinant methionyl human granulocyte colony stimulating factor. J Pharm Biomed Anal 17(2):283–289PubMedGoogle Scholar
  92. Rosenberg AS (2006) Effects of protein aggregates: an immunologic perspective. AAPS J 8(3):E501–E507PubMedCentralPubMedGoogle Scholar
  93. Schellekens H, Hennink WE, Brinks V (2013) The immunogenicity of polyethylene glycol: facts and fiction. Pharm Res 30(7):1729–1734PubMedGoogle Scholar
  94. Schulte S (2008) Use of albumin fusion technology to prolong the half-life of recombinant factor VIIa. Thromb Res 122(Suppl 4):S14–S19PubMedGoogle Scholar
  95. Schulte S (2009) Half-life extension through albumin fusion technologies. Thromb Res 124(Suppl 2):S6–S8PubMedGoogle Scholar
  96. Seidl A et al (2012) Tungsten-induced denaturation and aggregation of epoetin alfa during primary packaging as a cause of immunogenicity. Pharm Res 29(6):1454–1467PubMedCentralPubMedGoogle Scholar
  97. Shacter E (2000) Quantification and significance of protein oxidation in biological samples. Drug Metab Rev 32(3–4):307–326PubMedGoogle Scholar
  98. Shacter E, Beecham EJ, Covey JM, Kohn KW, Potter M (1988) Activated neutrophils induce prolonged DNA damage in neighboring cells. Carcinogenesis 9(12):2297–2304PubMedGoogle Scholar
  99. Shah D, Sah S, Wanchu A, Wu MX, Bhatnagar A (2013) Altered redox state and apoptosis in the pathogenesis of systemic lupus erythematosus. Immunobiology 218(4):620–627PubMedGoogle Scholar
  100. Sharma B (2007a) Immunogenicity of therapeutic proteins. Part 1: impact of product handling. Biotechnol Adv 25(3):310–317PubMedGoogle Scholar
  101. Sharma B (2007b) Immunogenicity of therapeutic proteins. Part 3: impact of manufacturing changes. Biotechnol Adv 25(3):325–331PubMedGoogle Scholar
  102. Shukla HD, Pitha PM (2012) Role of hsp90 in systemic lupus erythematosus and its clinical relevance. Autoimmune Dis 2012:728605PubMedCentralPubMedGoogle Scholar
  103. Silva JL, De Moura Gallo CV, Costa DC, Rangel LP (2014) Prion-like aggregation of mutant p53 in cancer. Trends Biochem Sci 39(6):260–267PubMedGoogle Scholar
  104. Sola RJ, Griebenow K (2009) Effects of glycosylation on the stability of protein pharmaceuticals. J Pharm Sci 98(4):1223–1245PubMedCentralPubMedGoogle Scholar
  105. Song J et al (2011) Bioinformatic approaches for predicting substrates of proteases. J Bioinform Comput Biol 9(1):149–178PubMedGoogle Scholar
  106. Song J et al (2012) PROSPER: an integrated feature-based tool for predicting protease substrate cleavage sites. PLoS One 7(11):e50300PubMedCentralPubMedGoogle Scholar
  107. Soong R, Brender JR, Macdonald PM, Ramamoorthy A (2009) Association of highly compact type II diabetes related islet amyloid polypeptide intermediate species at physiological temperature revealed by diffusion NMR spectroscopy. J Am Chem Soc 131(20):7079–7085PubMedGoogle Scholar
  108. Sorgato MC, Sartorelli L, Loschen G, Azzi A (1974) Oxygen radicals and hydrogen peroxide in rat brain mitochondria. FEBS Lett 45(1):92–95PubMedGoogle Scholar
  109. Stadtman ER (2006) Protein oxidation and aging. Free Radic Res 40(12):1250–1258PubMedGoogle Scholar
  110. Swaminathan J, Ehrhardt C (2012) Liposomal delivery of proteins and peptides. Expert Opin Drug Deliv 9(12):1489–1503PubMedGoogle Scholar
  111. Takalo M, Salminen A, Soininen H, Hiltunen M, Haapasalo A (2013) Protein aggregation and degradation mechanisms in neurodegenerative diseases. Am J Neurodegener Dis 2(1):1–14PubMedCentralPubMedGoogle Scholar
  112. Tarnai I et al (2007) Effect of C111T polymorphism in exon 9 of the catalase gene on blood catalase activity in different types of diabetes mellitus. Free Radic Res 41(7):806–811PubMedGoogle Scholar
  113. Tong P et al (2013) An engineered HIV-1 gp41 trimeric coiled coil with increased stability and anti-HIV-1 activity: implication for developing anti-HIV microbicides. J Antimicrob Chemother 68(11):2533–2544PubMedGoogle Scholar
  114. Torosantucci R, Schoneich C, Jiskoot W (2014) Oxidation of therapeutic proteins and peptides: structural and biological consequences. Pharm Res 31(3):541–553PubMedGoogle Scholar
  115. Tucker HM et al (2000) The plasmin system is induced by and degrades amyloid-beta aggregates. J Neurosci 20(11):3937–3946PubMedGoogle Scholar
  116. Ulrich AS (2002) Biophysical aspects of using liposomes as delivery vehicles. Biosci Rep 22(2):129–150PubMedGoogle Scholar
  117. Veronese FM, Mero A (2008) The impact of PEGylation on biological therapies. BioDrugs 22(5):315–329PubMedGoogle Scholar
  118. Vigneri R, Squatrito S, Sciacca L (2010) Insulin and its analogs: actions via insulin and IGF receptors. Acta Diabetol 47(4):271–278PubMedGoogle Scholar
  119. Vugmeyster Y, Xu X, Theil FP, Khawli LA, Leach MW (2012) Pharmacokinetics and toxicology of therapeutic proteins: advances and challenges. World J Biol Chem 3(4):73–92PubMedCentralPubMedGoogle Scholar
  120. Walsh G, Jefferis R (2006) Post-translational modifications in the context of therapeutic proteins. Nat Biotechnol 24(10):1241–1252PubMedGoogle Scholar
  121. Wang T, Xia Y (2012) Inducible nitric oxide synthase aggresome formation is mediated by nitric oxide. Biochem Biophys Res Commun 426(3):386–389PubMedGoogle Scholar
  122. Wang YS et al (2002) Structural and biological characterization of pegylated recombinant interferon alpha-2b and its therapeutic implications. Adv Drug Deliv Rev 54(4):547–570PubMedGoogle Scholar
  123. Wang YJ et al (2010) PEGylation markedly enhances the in vivo potency of recombinant human non-glycosylated erythropoietin: a comparison with glycosylated erythropoietin. J Control Release 145(3):306–313PubMedGoogle Scholar
  124. Wang XM, Lehky TJ, Brell JM, Dorsey SG (2012) Discovering cytokines as targets for chemotherapy-induced painful peripheral neuropathy. Cytokine 59(1):3–9PubMedCentralPubMedGoogle Scholar
  125. Weiner AL (1994) Liposomes for protein delivery: selecting manufacture and development processes. Immuno Methods 4(3):201–209Google Scholar
  126. Wolf P et al (2000) Topical treatment with liposomes containing T4 endonuclease V protects human skin in vivo from ultraviolet-induced upregulation of interleukin-10 and tumor necrosis factor-alpha. J Invest Dermatol 114(1):149–156PubMedGoogle Scholar
  127. Wondrak GT (2009) Redox-directed cancer therapeutics: molecular mechanisms and opportunities. Antioxid Redox Signal 11(12):3013–3069PubMedCentralPubMedGoogle Scholar
  128. Wyatt AR, Yerbury JJ, Ecroyd H, Wilson MR (2013) Extracellular chaperones and proteostasis. Annu Rev Biochem 82:295–322PubMedGoogle Scholar
  129. Xiao G, Gan LS (2013) Receptor-mediated endocytosis and brain delivery of therapeutic biologics. Int J Cell Biol 2013:703545PubMedCentralPubMedGoogle Scholar
  130. Xu X, Vugmeyster Y (2012) Challenges and opportunities in absorption, distribution, metabolism, and excretion studies of therapeutic biologics. AAPS J 14(4):781–791PubMedCentralPubMedGoogle Scholar
  131. Xu J et al (2011) Gain of function of mutant p53 by coaggregation with multiple tumor suppressors. Nat Chem Biol 7(5):285–295PubMedGoogle Scholar
  132. Yao Z, Dai W, Perry J, Brechbiel MW, Sung C (2004) Effect of albumin fusion on the biodistribution of interleukin-2. Cancer Immunol Immunother 53(5):404–410PubMedGoogle Scholar
  133. Yerbury JJ, Rybchyn MS, Easterbrook-Smith SB, Henriques C, Wilson MR (2005) The acute phase protein haptoglobin is a mammalian extracellular chaperone with an action similar to clusterin. Biochemistry 44(32):10914–10925PubMedGoogle Scholar
  134. Yin J et al (2005) Effects of excipients on the hydrogen peroxide-induced oxidation of methionine residues in granulocyte colony-stimulating factor. Pharm Res 22(1):141–147PubMedGoogle Scholar
  135. Zheng K, Yarmarkovich M, Bantog C, Bayer R, Patapoff TW (2014) Influence of glycosylation pattern on the molecular properties of monoclonal antibodies. MAbs 6(3):649–658PubMedCentralPubMedGoogle Scholar
  136. Zhong X, Wright JF (2013) Biological insights into therapeutic protein modifications throughout trafficking and their biopharmaceutical applications. Int J Cell Biol 2013:273086PubMedCentralPubMedGoogle Scholar
  137. Zinman B (2013) Newer insulin analogs: advances in basal insulin replacement. Diabetes Obes Metab 15(Suppl 1):6–10PubMedGoogle Scholar

Copyright information

© American Association of Pharmaceutical Scientists 2015

Authors and Affiliations

  1. 1.Division of Biotechnology Review and Research III, Office of Biotechnology ProductsCenter for Drug Evaluation and Research, Food and Drug AdministrationSilver SpringUSA

Personalised recommendations